GoodRx Holdings, Inc. announced that its condensed consolidated financial statements for the quarters ended March 31, 2026, and June 30, 2026, can no longer be relied upon. The decision was made after identifying errors in revenue recognition that resulted in an understatement of revenue from its Pharma Direct business.
Key Details
- Reason: Revenue from the Pharma Direct segment was not properly recognized in Q1 and Q2 2026, leading to an understatement of reported revenue and net income.
- Financial Impact: For the first six months of 2026, total revenue is expected to increase by approximately $29.8 million and net income by $14.8 million after restatement. The company will file amended 10-Q reports for the affected periods.
- Internal Controls: GoodRx anticipates reporting one or more material weaknesses in its internal control over financial reporting as a result of this issue.